Every material Form 8-K Bausch & Lomb Corp has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Director Nathalie Bernier resigned from Bausch + Lomb's board and its Science and Technology Committee, effective at the close of business on October 28, 2026, and said the resignation was not due to any disagreement with the company. The board does not currently intend to fill the vacancy, and the company agreed to pay her prorated cash compensation and fully accelerate her unvested 2026 restricted share units under a general mutual release.
Nathalie Bernier resigned from the Board and Science and Technology Committee, effective October 28, 2026
Board does not currently intend to fill the vacancy
Company will pay prorated cash compensation and fully vest her outstanding 2026 restricted share units
Filing states the resignation was not due to any disagreement with the company
Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion, up 7% from $1.281 billion a year earlier, and GAAP net income attributable to the company of $32 million, compared with a $28 million loss in the third quarter of 2025. The company raised its full-year 2026 revenue guidance and its adjusted EBITDA excluding acquired IPR&D guidance, which signals higher expected full-year results for shareholders.
Q3 2026 revenue was $1.375 billion, up $94 million or 7% from Q3 2025 (8% on a constant currency basis)
GAAP net income was $32 million, or $0.09 per share, versus a $28 million loss in Q3 2025
Full-year 2026 revenue guidance raised to $5.450 billion-$5.550 billion from $5.440 billion-$5.540 billion as of July 29, 2026
Full-year 2026 adjusted EBITDA excluding acquired IPR&D guidance raised to $1.090 billion-$1.140 billion from $1.025 billion-$1.075 billion
Brent Saunders left his roles as Bausch + Lomb chief executive and board member, effective October 12, 2026, under a mutually agreed separation. Thomas J. Appio, the board chairman who also serves as CEO of parent Bausch Health, was named interim CEO. The company said it expects to raise its full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D, based on preliminary third-quarter results.
Saunders' separation agreement provides a $75.5 million lump-sum cash payment and up to $50,000 in attorneys' fees, subject to a release of claims.
All of Saunders' outstanding equity awards, vested or unvested, were forfeited and cancelled.
Appio serves as interim CEO while remaining CEO of Bausch Health, the company's controlling shareholder.
The company expects to raise full-year 2026 adjusted EBITDA guidance excluding Acquired IPR&D; details are due with third-quarter results on October 28.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bausch & Lomb Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →